We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




First Direct Measurement of Dementia-Linked Proteins to Enable Early Alzheimer’s Detection

By LabMedica International staff writers
Posted on 10 Nov 2025

The disease process in Alzheimer’s begins long before memory loss or cognitive decline becomes apparent. More...

During this silent phase, misfolded proteins gradually form amyloid fibrils, which accumulate in the brain and cause irreversible damage. Current diagnostic techniques can rarely identify these early changes, meaning treatments often begin too late to be effective. Now, a breakthrough method could help detect the earliest stages of Alzheimer’s disease years before symptoms appear.

For the first time, researchers at Utrecht University (Utrecht, Netherlands) have made the growth of harmful protein clumps involved in dementias such as Alzheimer’s, Parkinson’s, and Huntington’s directly measurable — even in blood samples. The team, in collaboration with colleagues from international institutes, has developed FibrilPaint — a new class of molecules that “paint” the earliest fibril formations. FibrilPaint binds specifically to the thread-like amyloid protein aggregates characteristic of dementia and emits fluorescent light when exposed to specialized imaging equipment.

This fluorescence not only confirms the presence of the fibrils but also reveals their length and growth stage, offering a measurable indicator of disease progression. Importantly, FibrilPaint allows scientists to analyze blood and cerebrospinal fluid directly, eliminating the complex, time-consuming pretreatment steps required by existing methods.

The researchers believe FibrilPaint could revolutionize both early diagnosis and drug development for neurodegenerative diseases. By tracking disease progression in unprecedented detail, the technique, published in the journal PNAS, will allow clinicians to evaluate treatment effectiveness in real time.

“With our technique, we will soon be able to monitor the progression of the disease much more precisely and determine whether a treatment is effective,” said Françoise Dekker, a chemist at Utrecht University. “Our technique will eventually allow us to follow the course of the disease much more accurately and see whether a treatment really works.”

Related Links:
Utrecht University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Automatic CLIA Analyzer
Shine i6000
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.